Home
Charts
Search
Watchlist
Products
All IPOs
₹343 - 343
Q-Line Biotech Ltd
TradingIPOSME
₹343 - 343
We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
Lot400Min Invest₹2,74,400Face Value₹10Issue Size₹214 CrFresh Issue₹214 CrListing Price₹452CMP₹530
Timeline
21 May
Bidding opens
25 May
Bidding closes
26 May
Allotment
27 May
Refund & demat credit
29 May
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹214 Cr0.63 Cr shares
Fresh Issue₹214 Cr
Face Value₹10
Lot Size400 shares
ReservationQIB 49.99% · NII 15.01% · RETAIL 35%
Application Sizes
Retail₹2,74,4001-1 lots
sNII₹2,74,400from 2 lots
bNII₹10,97,600from 8 lots
Managers & Registrar
Lead ManagerHem Securities Limited
Co-ManagerShare India Capital Services Private Limited
RegistrarPurva Sharegistry (I) Pvt Ltd
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group92.22%67.53%Public7.78%32.47%
Objects of the Issue
- To meet Working Capital requirements
- Repayment of certain borrowing availed by the Company, in part or full
- General corporate purposes
Anchor Book
Bid Date20-May-2026Shares17,81,200Amount₹61 Cr30-day lock-in24-Jun-202690-day lock-in23-Aug-2026
Financials
Profit & Loss
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| RevenueCr | 183 | 204 | 313 | 342 |
| Operating ProfitCr | 34 | 38 | 71 | 98 |
| OPM% | 18.4 | 18.7 | 22.5 | 28.7 |
| PBTCr | 30 | 31 | 35 | 73 |
| PATCr | 21 | 22 | 16 | 56 |
| EPS | 20 | 22 | 12 | 35 |
Balance Sheet
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity CapitalCr | 2 | 2 | 2 | 16 |
| ReservesCr | 126 | 160 | 188 | 230 |
| BorrowingsCr | 74 | 97 | 165 | 225 |
| Fixed AssetsCr | - | - | - | 145 |
| Total AssetsCr | 252 | 339 | 455 | 559 |
Cash Flow
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Operating Cash FlowCr | 25 | -24 | 17 | 16 |
| Investing Cash FlowCr | -26 | -45 | -77 | -29 |
| Financing Cash FlowCr | 26 | 17 | 53 | 42 |
| Net Cash FlowCr | 25 | -52 | -7 | 29 |
Strengths & Risks
Strengths · as stated in the DRHP
- Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.
- Diversified product portfolio with focus on IVD industry.
- Widespread distribution network with a presence across all four regions.
- Long standing relationships with customers.
- Track record of healthy financial performance.
- Experienced Promoter and Management team.
Strategies · as stated in the DRHP
- Expanding presence in existing markets and entering new ones.
- Exploring Strategic Alliances in CMO/CDMO Services.
- Grow manufacturing and production capacities aligned with the "Make In India" initiative of GoI.
- Expanding our existing product portfolio.
Risks · as stated in the DRHP
- Any disruption, stoppage, slowdown or shutdown in the company manufacturing facilities or process or research and development activities could adversely affect its business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of the company raw materials, trade goods from its suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of the company products and has an adverse effect on the company business, financial condition, cash flows and results of operations.
- The company business is dependent on the sale of its products through distributors which also include the company group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of its products and could negatively impact the company business, results of operations, financial conditions and cash flows.
- The company is dependent on certain key suppliers to procure a significant portion of the company Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in its operations, which could has an adverse effect on the company business, financial condition, results of operations and cash flows.
- The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operates the company business.
- For manufacturing of its machines and reagents, the company is dependent on the agreement with the European companies, any failures to renew the agreement or entering into the agreement on the terms which is not favourable for its may impact the company business operations, financial condition and cash flows.